GeneMatrix Inc. of Seongnam-si at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers Trader

GeneMatrix Inc.

Korea Bio Park B Bldg. 8F, 700 Daewangpangyo-ro, Bundang-gu, 13488 Seongnam-si
Korea, Republic
Telephone +82 31 6282020
Fax +82 31 6282001

Hall map

MEDICA 2018 hall map (Hall 3): stand J16

Fairground map

MEDICA 2018 fairground map: Hall 3


Ted Kwon


Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Diagnostic rapid tests

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.01  DNA testing

DNA testing

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR)

Our products

Product category: Diagnostic rapid tests


Bead array-based detection and genotyping of 40 HPV genotypes
OmniPlex-HPV simultaneously identifies 40 HPV genotypes (15 high-risk, 4 probable high-risk, and 21 low-risk) in a single tube using Liquid Bead Microarray method and can report results within the same day through easy and fast analysis process.

More Less

About us

Company details

“Genematrix aims to be a global medical 
And bio-technology company that 
Realizes healthy living”
Medical and bio-technology is the key field that can lead and shape the 4th industrial revolution, including smart healthcare, new drug, and medical devices.

Genematrix has focused its R&D on convergence technology, which consistently grows and has influence in the world market, and made every effort on commercialization since it has been listed on the KOSDAQ as a technology innovation corporation in 2009. Genematrix has developed core platform technologies in molecular diagnostics that differentiated itself from existing technologies, realizing that the personalized medicine is the future of the medical and biotech industries. Genematrix is also making efforts to develop new natural pharmaceutical materials and new drugs for disease treatment.

Genematrix does not only intend to maximize shareholder value by constantly creating growth momentum through partnering in the global market, but also to fulfill the company's role in the people-oriented 4th industry by taking a social responsibility in such field promoting national health and creating new jobs.


More Less